Latest Insider Transactions at Gilead Sciences, Inc. (GILD)
This section provides a real-time view of insider transactions for Gilead Sciences, Inc. (GILD). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of GILEAD SCIENCES, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of GILEAD SCIENCES, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 10
2022
|
Merdad Parsey Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,505
-7.83%
|
$199,785
$57.92 P/Share
|
|
Mar 10
2022
|
Merdad Parsey Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,612
+8.17%
|
-
|
|
Mar 10
2022
|
Diane E. Wilfong SVP, Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
935
-3.4%
|
$53,295
$57.92 P/Share
|
|
Mar 10
2022
|
Diane E. Wilfong SVP, Controller & CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,297
+5.79%
|
-
|
|
Mar 10
2022
|
Brett A Pletcher EVP,Corp Affairs & Gen Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,089
-5.45%
|
$119,073
$57.92 P/Share
|
|
Mar 10
2022
|
Brett A Pletcher EVP,Corp Affairs & Gen Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,723
+7.21%
|
-
|
|
Mar 10
2022
|
Daniel Patrick O'Day Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,052
-4.24%
|
$629,964
$57.92 P/Share
|
|
Mar 10
2022
|
Daniel Patrick O'Day Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
24,003
+4.51%
|
-
|
|
Mar 01
2022
|
Daniel Patrick O'Day Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
23,245
-8.95%
|
$1,394,700
$60.26 P/Share
|
|
Mar 01
2022
|
Daniel Patrick O'Day Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
54,284
+9.58%
|
-
|
|
Feb 15
2022
|
Merdad Parsey Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
348
+0.83%
|
$18,096
$52.13 P/Share
|
|
Feb 15
2022
|
Brett A Pletcher EVP,Corp Affairs & Gen Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
348
+1.05%
|
$18,096
$52.13 P/Share
|
|
Feb 15
2022
|
Andrew D Dickinson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
348
+0.54%
|
$18,096
$52.13 P/Share
|
|
Feb 09
2022
|
Brett A Pletcher EVP,Corp Affairs & Gen Counsel |
SELL
Open market or private sale
|
Direct |
1,691
-4.93%
|
$106,533
$63.89 P/Share
|
|
Feb 06
2022
|
Diane E. Wilfong SVP, Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
520
-2.1%
|
$32,760
$63.9 P/Share
|
|
Feb 06
2022
|
Diane E. Wilfong SVP, Controller & CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,864
+7.01%
|
-
|
|
Feb 06
2022
|
Brett A Pletcher EVP,Corp Affairs & Gen Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,036
-2.93%
|
$65,268
$63.9 P/Share
|
|
Feb 06
2022
|
Brett A Pletcher EVP,Corp Affairs & Gen Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,727
+7.17%
|
-
|
|
Feb 06
2022
|
Andrew D Dickinson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
767
-1.27%
|
$48,321
$63.9 P/Share
|
|
Feb 06
2022
|
Andrew D Dickinson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,817
+2.92%
|
-
|
|
Feb 01
2022
|
Brett A Pletcher EVP,Corp Affairs & Gen Counsel |
SELL
Open market or private sale
|
Direct |
14,061
-30.15%
|
$956,148
$68.54 P/Share
|
|
Jan 26
2022
|
Brett A Pletcher EVP,Corp Affairs & Gen Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
5,681
-10.86%
|
$380,627
$67.34 P/Share
|
|
Jan 26
2022
|
Brett A Pletcher EVP,Corp Affairs & Gen Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
35,004
+29.65%
|
-
|
|
Jan 26
2022
|
Andrew D Dickinson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,616
-5.81%
|
$242,272
$67.34 P/Share
|
|
Jan 26
2022
|
Andrew D Dickinson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,176
+22.68%
|
-
|
|
Jan 26
2022
|
Diane E. Wilfong SVP, Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
394
-1.69%
|
$26,398
$67.34 P/Share
|
|
Jan 26
2022
|
Diane E. Wilfong SVP, Controller & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
2,871
+5.97%
|
-
|
|
Jan 26
2022
|
Merdad Parsey Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,298
+35.33%
|
-
|
|
Jan 26
2022
|
Daniel Patrick O'Day Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
33,833
-14.15%
|
$2,266,811
$67.34 P/Share
|
|
Jan 26
2022
|
Daniel Patrick O'Day Chairman & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
146,678
+27.36%
|
-
|
|
Jan 26
2022
|
Johanna Mercier Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,630
+37.71%
|
-
|
|
Dec 08
2021
|
Jeffrey Bluestone Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,041
+50.0%
|
-
|
|
Nov 10
2021
|
Andrew D Dickinson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
870
-2.24%
|
$58,290
$67.32 P/Share
|
|
Nov 10
2021
|
Andrew D Dickinson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,913
+4.69%
|
-
|
|
Nov 10
2021
|
Merdad Parsey Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,320
-12.1%
|
$155,440
$67.32 P/Share
|
|
Nov 10
2021
|
Merdad Parsey Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,100
+21.0%
|
-
|
|
Oct 22
2021
|
Anthony Welters Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,368
+50.0%
|
-
|
|
Aug 17
2021
|
Diane E. Wilfong SVP, Controller & CAO |
SELL
Open market or private sale
|
Direct |
13,610
-40.02%
|
$979,920
$72.5 P/Share
|
|
Aug 17
2021
|
Diane E. Wilfong SVP, Controller & CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,610
+17.3%
|
$911,870
$67.56 P/Share
|
|
Aug 15
2021
|
Andrew D Dickinson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1
+0.0%
|
$55
$55.08 P/Share
|
|
Aug 15
2021
|
Merdad Parsey Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1
+0.01%
|
$55
$55.08 P/Share
|
|
Aug 15
2021
|
Brett A Pletcher EVP,Corp Affairs & Gen Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
32
+0.11%
|
$1,760
$55.08 P/Share
|
|
Aug 10
2021
|
Diane E. Wilfong SVP, Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
907
-4.26%
|
$62,583
$69.24 P/Share
|
|
Aug 10
2021
|
Diane E. Wilfong SVP, Controller & CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,480
+10.43%
|
-
|
|
Jul 24
2021
|
Johanna Mercier Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,425
-21.99%
|
$236,325
$69.02 P/Share
|
|
Jul 24
2021
|
Johanna Mercier Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,505
+32.52%
|
-
|
|
Jun 15
2021
|
Javier Rodriguez Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,838
+50.0%
|
-
|
|
Jun 10
2021
|
Andrew D Dickinson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,605
-4.16%
|
$110,745
$69.29 P/Share
|
|
Jun 10
2021
|
Andrew D Dickinson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,646
+8.64%
|
-
|
|
May 06
2021
|
Harish Manwani Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,936
+25.51%
|
-
|